Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/198337
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Martínez Casanova, Javier | - |
dc.contributor.author | Esteve Pitarch, Erika | - |
dc.contributor.author | Colom Codina, Helena | - |
dc.contributor.author | Gumucio Sanguino, Víctor Daniel | - |
dc.contributor.author | Cobo Sacristán, Sara | - |
dc.contributor.author | Shaw, Evelyn | - |
dc.contributor.author | Maisterra Santos, Kristel | - |
dc.contributor.author | Sabater Riera, Joan | - |
dc.contributor.author | Pérez Fernandez, Xosé L. | - |
dc.contributor.author | Rigo Bonnin, Raül | - |
dc.contributor.author | Tubau Quintano, Fe | - |
dc.contributor.author | Carratalà, Jordi | - |
dc.contributor.author | Padullés Zamora, Ariadna | - |
dc.date.accessioned | 2023-05-23T11:37:04Z | - |
dc.date.available | 2023-05-23T11:37:04Z | - |
dc.date.issued | 2023-03-07 | - |
dc.identifier.issn | 2079-6382 | - |
dc.identifier.uri | http://hdl.handle.net/2445/198337 | - |
dc.description.abstract | Critically ill patients undergo significant pathophysiological changes that affect antibiotic pharmacokinetics. Piperacillin/tazobactam administered by continuous infusion (CI) improves pharmacokinetic/pharmacodynamic (PK/PD) target attainment. This study aimed to characterize piperacillin PK after CI administration of piperacillin/tazobactam in critically ill adult patients with preserved renal function and to determine the empirical optimal dosing regimen. A total of 218 piperacillin concentrations from 106 patients were simultaneously analyzed through the population PK approach. A two-compartment linear model best described the data. Creatinine clearance (CLCR) estimated by CKD-EPI was the covariate, the most predictive factor of piperacillin clearance (CL) interindividual variability. The mean (relative standard error) parameter estimates for the final model were: CL: 12.0 L/h (6.03%); central and peripheral compartment distribution volumes: 20.7 L (8.94%) and 62.4 L (50.80%), respectively; intercompartmental clearance: 4.8 L/h (26.4%). For the PK/PD target of 100% fT(>1xMIC), 12 g of piperacillin provide a probability of target attainment > 90% for MIC < 16 mg/L, regardless of CLCR, but higher doses are needed for MIC = 16 mg/L when CLCR > 100 mL/min. For 100% fT(>4xMIC), the highest dose (24 g/24 h) was not sufficient to ensure adequate exposure, except for MICs of 1 and 4 mg/L. Our model can be used as a support tool for initial dose guidance and during therapeutic drug monitoring. | - |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/antibiotics12030531 | - |
dc.relation.ispartof | Antibiotics, 2023, vol. 12, num. 3, p. 531 | - |
dc.relation.uri | https://doi.org/10.3390/antibiotics12030531 | - |
dc.rights | cc by (c) Martínez Casanova, Javier et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | - |
dc.subject.classification | Antibiòtics betalactàmics | - |
dc.subject.classification | Farmacocinètica | - |
dc.subject.classification | Farmacovigilància | - |
dc.subject.other | Beta lactam antibiotics | - |
dc.subject.other | Pharmacokinetics | - |
dc.subject.other | Drug monitoring | - |
dc.title | Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-04-21T12:19:37Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36978398 | - |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
antibiotics-12-00531.pdf | 3.35 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License